Geographic proximity to buprenorphine treatment providers in the U.S.

Source:

Langabeer, J., Stotts, A. L., Cortez, A., Tortolero, G., & Champagne-Langabeer, T. (2020). Geographic proximity to buprenorphine treatment providers in the US. Drug and alcohol dependence, 108131.

Highlights

•Access to treatment remains a concern for patients with opioid use disorder.

•Geospatial buffering model estimates 28 million Americans outside 10 miles.

•Central and western U.S. region persist with high ratios between need and providers.

•Low access to transportation, long distances equate to lower engagement in treatment.